Hyloris Pharmaceuticals SA

Brussels Stock Exchange HYL.BR

Hyloris Pharmaceuticals SA Price to Sales Ratio (P/S) on January 14, 2025: 75.67

Hyloris Pharmaceuticals SA Price to Sales Ratio (P/S) is 75.67 on January 14, 2025, a -56.08% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Hyloris Pharmaceuticals SA 52-week high Price to Sales Ratio (P/S) is 176.42 on February 01, 2024, which is 133.15% above the current Price to Sales Ratio (P/S).
Hyloris Pharmaceuticals SA 52-week low Price to Sales Ratio (P/S) is 42.51 on November 18, 2024, which is -43.82% below the current Price to Sales Ratio (P/S).
Hyloris Pharmaceuticals SA average Price to Sales Ratio (P/S) for the last 52 weeks is 109.08.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Brussels Stock Exchange: HYL.BR

Hyloris Pharmaceuticals SA

CEO	Mr. Stijn Van Rompay
IPO Date	June 29, 2020
Location	Belgium
Headquarters	Boulevard Gustave Kleyer 17
Employees	41
Sector	Health Care
Industries Pharmaceuticals

Description

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.

Key trends

Past 5 years